DME prior authorization for FES/NMES

When billing for listed FES/NMES DME items (for example HCPCS E0764, E0745, E0731, A4595), prior authorization is implied — coverage is contingent on meeting the policy’s selection/medical necessity criteria for the specific device and indication.

• Covered HCPCS/ CPT/ ICD codes are conditional on meeting device-specific selection criteria.
• Provide documentation that the patient meets the clinical criteria referenced in the policy when requesting authorization.

Prior authorization for implantable and external NMES/FES

Certain implantable and external neuromuscular stimulator devices (examples include HCPCS E0745 and implantable neurostimulator codes L8685–L8689) are covered only if selection criteria are met — prior authorization is implied when those criteria apply.

• Include device model and evidence the patient meets the policy’s selection criteria with the PA request.
• Implantable device claims (L8685–L8689) require documentation of indication and candidacy.

Prior authorization — implanted diaphragmatic pacing

For diaphragmatic/diaphragm pacing implants, if prior authorization is requested include documentation of laparoscopic diaphragm motor‑point mapping and pre‑implant respiratory function (e.g., FVC) and evidence of candidacy per the policy’s selection criteria.

• Document motor point mapping and intra‑muscular electrode stimulation testing performed during implantation.
• Provide baseline respiratory measures and justification that pacing would allow ≥4 continuous hours off mechanical ventilation when applicable.

Implanted sacral root stimulator prior authorization

Implanted sacral anterior root stimulators (e.g., Vocare/Finetech‑Brindley) are supported in selected supra‑sacral SCI patients; prior authorization requests should include evidence of reflex testing and cystometry consistent with implant candidacy.

• Provide documentation that 3 of 4 non‑vesical sacral segment reflexes are present.
• Include cystometry showing phasic detrusor pressure rise (≥35 mm H2O female; ≥50 cm H2O male) and trial response data.

Prior authorization not specified in this section

The policy text contains no explicit payer prior‑authorization code requirements for many background device discussions; when PA processes are used, the document supplies evidentiary context rather than administrative code triggers.

• Absence of explicit PA codes in these sections means PA expectations derive from covered‑when‑selection‑criteria‑met language elsewhere.
• Use the device‑specific selection criteria and codes elsewhere in the policy to determine PA needs.

Clinical trial eligibility noted

Clinical trial eligibility criteria (e.g., AHI ≥20 events/hour for phrenic nerve stimulation trials) are described for research enrollment but do not substitute for payer prior authorization; include trial‑level evidence only as supporting documentation when applicable.

• Trial enrollment criteria (AHI ≥20, medically stable ≥30 days) are informational — provide diagnostic testing and prior therapy documentation for PA.
• Do not assume trial criteria equal PA criteria unless payer explicitly adopts them.

Prior authorization for implantable phrenic nerve stimulators

For implantable phrenic nerve stimulators (Remede System), prior authorization requests should document diagnosis of moderate‑to‑severe central sleep apnea, prior standard therapies attempted, and device candidacy (sleep testing distinguishing central vs obstructive events).

• Include PSG/AHI results and prior trials of mask‑based therapy, oxygen, or pharmacotherapy.
• Note the Remede System contraindications (active infection, MRI dependence) when assessing candidacy.

Prior authorization expectations for SNS

Given mixed or unfavorable evidence for sacral neuromodulation (SNS) in chronic constipation and reported complication rates, prior authorization should require documentation of refractory symptoms, prior conservative therapies tried, and explicit discussion of uncertain benefit.

• Provide bowel diaries, standardized constipation scores, record of prior therapies attempted, and test‑stimulation response if available.
• Highlight known device‑related adverse events and prior trial outcomes in the PA submission.

Prior authorization for chronic device use (wrist‑worn PNS)

When requesting long‑term/home use coverage for wrist‑worn peripheral nerve stimulation devices (e.g., Cala/TAPS), consider prior authorization supported by baseline and follow‑up objective clinician‑ and device‑recorded measures demonstrating benefit.

• Submit baseline TETRAS and BF‑ADL scores and device accelerometer usage logs showing improvements over time.
• Document prescribed regimen (e.g., twice‑daily use), duration of home trial, and clinician assessments.

Prior authorization expectation (Cala/TAPS)

Studies of Cala/TAPS included prescription processes and collection of device logs and patient‑reported outcomes; PA requests for similar devices should supply diagnosis confirmation, device usage logs, and measured benefit as documented in trials.

• Provide physician confirmation of neurologic diagnosis on the prescription form and screening questionnaire results.
• Attach device‑recorded tremor power and ADL changes from the monitored trial period.

Prior authorization likely required for FDA‑cleared wearable devices

Coverage decisions for FDA‑cleared wearable NMES or FES technologies (e.g., geko, MyoCycle Home) may require prior authorization with documentation of the indication, device model/FDA status, and supporting clinical evidence aligned to the policy criteria.

• Include device model, FDA clearance information, indication being treated, and objective baseline and follow‑up functional or metabolic measures.
• For disposable wearable devices (e.g., geko), note intended use period and any device log data collected.

TOMAC prior authorization evidence

For TOMAC (Tonic Motor Activation) prior authorization include the RESTFUL randomized trial and extension study results (CGI‑I responder rates, IRLS score changes) and documentation that the patient is medication‑refractory when applicable.

• Attach RESTFUL trial outcomes (45% vs 16% CGI‑I responder at 4 weeks) and extension study durability data to support the PA.
• Document prior medication trials and refractory status in the medical record.

Device use should align with trial inclusion criteria

Prior authorization requests for devices studied in trials should demonstrate that the patient matches trial inclusion criteria (for example, TOMAC: medication‑refractory moderate‑to‑severe RLS; Walkasins: impaired plantar sensation plus FGA <23) and include relevant outcome measures and prior treatment history.

• Provide baseline functional measures (e.g., IRLS for RLS or FGA for Walkasins) and documentation of prior therapies attempted.
• When device use deviates from trial populations, include justification and supporting evidence.

Prior authorization may be required for Walkasins

Because evidence for lower‑limb sensory prostheses (e.g., Walkasins) is limited, prior authorization may be required; include documentation of peripheral neuropathy with impaired plantar sensation, FGA <23, ability to perceive tactile cues above the ankle, and baseline/follow‑up gait outcomes.

• Submit FGA, gait speed, TUG and documentation of impaired plantar sensation and ability to sense device cues.
• If long‑term benefit is asserted, provide trial data or study participation details to support ongoing coverage.

Step therapy for diaphragmatic/phrenic pacing

Diaphragmatic/phrenic pacing is reserved for refractory respiratory indications after failure of other therapies (mask‑based therapies, oxygen, pharmacotherapy); document prior conservative therapy attempts and rationale for implantable pacing.

• Show prior use and intolerance/failure of mask‑based therapies or other standard treatments.
• Provide objective respiratory testing and evidence supporting diaphragmatic pacing candidacy.

Conservative therapy prior to FES

For foot‑drop FES, payers may expect a trial of standard conservative therapy (AFO or exercise) before approving FES devices because some trials show comparable or superior effects with these conservative options.

• Document prior use of an AFO or supervised exercise therapy and clinical response.
• Include rationale if FES is sought without prior conservative therapy.

Comparative device sequencing (FES vs AFO)

Comparative trials often evaluate FES versus ankle‑foot orthoses (AFO); when sequencing devices, document prior orthotic trials and patient preference or demonstrated orthotic limitations to support progression to FES.

• Provide results of prior AFO use, device preference assessments, and functional test results (10‑m walk, 6‑min walk).
• If FES is requested after AFO, include objective measures showing inadequate function with orthosis.

Test stimulation before permanent implant

Clinical trial designs for implantable neuromodulation commonly required test stimulation and demonstration of benefit before permanent implantation; include test‑stimulation records and documented response when seeking coverage for permanent implants.

• Attach test‑stimulation monitoring results, symptom diaries, and documented clinical response prior to permanent implant request.
• Provide records of prior conservative management and why permanent implantation is indicated.

Step: prior PT trial (TLNS/PoNS)

For TLNS/PoNS adjunctive use, document a prior plateau on conventional physical therapy and provide objective baseline and follow‑up balance assessments (e.g., SOT, DGI) to support coverage.

• Include documentation of a documented plateau in PT and pre/post SOT or DGI scores.
• Show the course and duration of prior PT and objective evidence of persistent deficit.

Training completion and prior device necessity

Document completion of at least 32 physical therapy sessions over a 3‑month Parastep training program and evidence that the original device met medical necessity when requesting FES for ambulation or device replacement.

• Provide PT session logs showing ≥32 sessions over 3 months.
• For replacements, include warranty/repair attempts and that the original device met policy criteria.

Form‑fitting garment documentation

When a form‑fitting conductive garment (HCPCS E0731) is used to deliver NMES, include a physician prescription stating the garment is FDA‑marketed and justification why conventional electrodes are impractical or contraindicated.

• Attach documentation that the garment is FDA‑approved for marketing.
• Provide clinical justification (large stimulation area, skin condition, stimulation under cast) for garment use.

Medical necessity documentation for billed codes

When billing HCPCS/CPT codes for stimulators, electrodes, leads, or implantable components that are conditioned on selection criteria, include supporting medical necessity documentation demonstrating the patient meets the policy’s criteria for the specific code and device.

• Correlate each billed HCPCS/CPT code with the policy criterion satisfied in the medical record.
• Include objective outcome measures and prior therapy history relevant to the coded device.

Device prescription and procedural documentation (DPS)

Series of diaphragm pacing implantations reported laparoscopic diaphragm motor‑point mapping and intra‑muscular electrode implantation with perioperative assessments; include operative notes and motor‑point mapping/stimulation testing in records when submitting implant or PA requests.

• Submit operative reports documenting laparoscopic motor‑point mapping and intra‑muscular electrode placement.
• Include perioperative respiratory measures (e.g., FVC) and stimulation testing results.

Implant selection documentation (sacral stimulators)

For implanted sacral anterior root stimulation, document the presence of 3 of 4 non‑vesical sacral reflexes and cystometry demonstrating the phasic detrusor pressure rise thresholds specified in the policy.

• Provide cystometry results showing phasic detrusor pressure rise (≥35 mm H2O female; ≥50 cm H2O male).
• Document presence of ankle jerks, bulbocavernosus reflex, anal skin reflex, or reflex erection as applicable.

Clinical outcome documentation

Include objective clinical outcome measures (e.g., 10‑m walk, 6‑min walk, gait speed, FGA, Stroke Impact Scale) and device‑recorded metrics when submitting evidence of benefit for FES/NMES devices.

• Attach baseline and follow‑up gait/mobility measures and device logs demonstrating functional change.
• Report adverse events and therapy adherence as part of follow‑up documentation.

Provide operative/device history and replacement justification

When requesting replacement of an implanted device (e.g., Remede generator), provide operative/device history and justification for replacement such as documented battery depletion or device end‑of‑life evidence (mean Remede battery life ~4.2 years reported).

• Include prior implant operative report, device interrogation showing battery status, and reason for replacement.
• Cite observed mean battery life data if relevant to timing of replacement.

Documentation of test stimulation response and prior conservative management

For permanent implantable neuromodulation devices (e.g., SNS for constipation), provide test‑stimulation records, symptom diaries, validated symptom scores, and documentation of prior conservative management as prerequisites for coverage review.

• Attach test‑stimulation response documentation and bowel diaries or standardized constipation/incontinence scores.
• Detail prior therapies attempted and duration of conservative management.

Include device usage logs and objective tremor outcomes

To support continued home‑use coverage of wrist‑worn tremor devices, include device usage logs, on‑board accelerometry tremor power metrics, clinician‑rated TETRAS and patient BF‑ADL scores at baseline and follow‑up demonstrating benefit.

• Provide device session logs, objective accelerometer tremor power pre/post metrics, and clinician/patient rated outcome scales over the home‑use period.
• Report adverse events (e.g., skin irritation) and adherence rates.

Use of ICD‑10‑CM G25.0 and diagnostic documentation

When using the ET diagnosis code (ICD‑10‑CM G25.0) as part of enrollment or coverage logic, ensure at least two diagnostic claims or equivalent diagnostic documentation are present and that the physician confirmed the neurologic diagnosis on the prescription form, as done in cited trials.

• Provide ≥2 medical claims with ICD‑10‑CM G25.0 separated by ≥7 days within the last 3 years or equivalent documentation.
• Include physician confirmation of diagnosis on prescription and screening questionnaire results.

FES ambulation selection criteria not met — denial risk

Failure to meet all Parastep (FES ambulation) selection criteria (intact lower motor units, ability to transfer/stand, completion of ≥32 PT sessions over 3 months, etc.) will render FES for walking not medically necessary and is a basis for denial.

• Confirm intact lower motor units (L1 and below), ability to transfer independently and stand ≥3 minutes, hand function to operate controls.
• Provide PT training records showing completion of ≥32 sessions over 3 months.

Excessive NMES daily use (>2 hours) — denial risk

Use of NMES for more than 2 hours within a 24‑hour period is considered not medically necessary per the policy; claims documenting excessive daily use risk denial.

• Ensure prescribed and documented daily NMES use does not exceed 2 hours in any 24‑hour period.
• If longer use is proposed, provide explicit supporting clinical justification and trial evidence.

Not‑covered HCPCS triggers — denial risk

Billing with HCPCS codes that the policy lists as 'not covered for indications listed in the CPB' (examples include A4544, E0743, L8720/L8721, A4560) may trigger claim denials; ensure codes align with covered indications and documented selection criteria.

• Verify the HCPCS billed matches a covered indication and that selection criteria supporting coverage are documented.
• Avoid using HCPCS flagged as not covered for the CPB indications unless coverage criteria are explicitly met.

Not‑covered peroneal stimulator/system codes (e.g., E0770) — denial risk

Use of peroneal stimulator/system HCPCS codes explicitly listed as not covered for CPB indications (for example E0770) may trigger denials; submit detailed clinical justification and evidence if using these codes for off‑label or non‑CPB indications.

• If E0770 or similar codes are submitted, include documentation that the indication falls within a covered exception and meets policy criteria.
• Provide trial data or device‑specific evidence to support medical necessity for non‑covered code use.

TEBS limited utility — denial risk

Transurethral electrical bladder stimulation (TEBS) has limited clinical benefit and programs have ceased accepting new patients; requests for TEBS as effective therapy are at risk for denial due to time‑intensive procedure and lack of durable benefit in trials.

• Provide rigorous objective evidence if asserting benefit for TEBS in a specific patient; otherwise, expect nonsupport for coverage.
• Highlight that TEBS trials demonstrated limited urodynamic and functional improvement.

No explicit administrative prior authorization triggers present

There is no explicit administrative prior authorization or coding denial trigger in many background sections — reviewers should rely on the policy’s coverage statements (covered when selection criteria are met) and the listed code tables to determine PA needs.

• Use the policy’s covered‑when‑selection‑criteria language and specific code lists to decide when PA is required.
• Background evidence summaries alone do not constitute administrative PA rules.

Remede System contraindications — denial risk

Claims for the Remede System submitted for patients with active infection or those requiring MRI are contraindicated and may be denied; verify contraindications before authorization and document absence of active infection and MRI dependence.

• Document absence of active infection and whether the patient requires MRI before approving Remede device implantation.
• Include PSG/AHI data and prior therapy attempts to support device candidacy.

Adverse events and limited efficacy (SNS) — denial risk

High device‑related adverse event rates and inconsistent efficacy for sacral neuromodulation in constipation are documented; lack of demonstrated benefit or complications may lead to coverage denial for SNS in chronic constipation.

• Provide long‑term follow‑up data, complication history, and objective symptom measures to support a PA for SNS.
• Be aware that RCTs for constipation have not consistently shown benefit and reported substantial AEs.

Evidence limitations may affect coverage — denial risk

Single‑session, open‑label, or small uncontrolled studies without durability data may not support long‑term coverage decisions; absence of randomized or durable evidence is a common basis for denial of chronic home‑use claims.

• Attach randomized controlled trial data or longer‑term controlled follow‑up when available.
• If only single‑session or open‑label evidence exists, expect additional documentation requests or denial for long‑term coverage.

Data insufficiency may affect coverage decisions

Missing or poor‑quality device measurement data (e.g., incomplete accelerometry, voluntary survey nonresponse) in real‑world datasets can prevent demonstration of effectiveness and may result in denial or requests for additional documentation.

• Ensure device‑recorded data are complete and linked to clinician assessments when submitted for PA or continued coverage.
• Provide objective pre/post device metrics rather than solely voluntary surveys.

Evidence insufficiency for wearable NMES — denial risk

Lack of robust clinical evidence for wearable NMES devices (e.g., geko T‑3/W‑3) may trigger coverage denial or requests for supporting documentation demonstrating clinical value for the specific indication.

• When seeking coverage for wearable NMES, include device‑specific FDA clearance details and clinical evidence supporting the intended use.
• Be prepared to supply device logs, outcome measures, and rationale when evidence is limited.

Insufficient group‑level efficacy in intermittent claudication trial — denial risk

A multicenter RCT of NMES for intermittent claudication failed to show statistically significant improvement in absolute walking distance across the whole cohort at 3 months; lack of group‑level efficacy can be cited to deny broad coverage for IC populations.

• Document why the patient may differ from trial populations (e.g., mild claudication subgroup) if asserting benefit.
• Consider supervised exercise therapy (SET) evidence and prior SET attempts in the record.

Evidence limited outside studied populations — denial risk

Lack of evidence for populations outside those studied (for example, TOMAC data largely in medication‑refractory moderate‑to‑severe RLS) may lead to denial when patients do not match trial populations; ensure alignment with trial inclusion or provide robust justification.

• If treating medication‑naïve or mild RLS patients with TOMAC, provide explicit supportive evidence as trials focused on refractory moderate‑to‑severe cases.
• For devices studied in specific cohorts, include matching baseline severity and prior therapy history in PA documentation.

Supply documentation of criteria, training completion, and device warranty/repair history

Provide clinical documentation showing the patient meets device‑specific medical necessity criteria, evidence of training completion (e.g., ≥32 PT sessions for Parastep), and device warranty/repair attempts for replacement requests.

• Attach PT training logs, device repair history, and statements regarding warranty status for replacement claims.
• Ensure clinical notes explicitly map patient findings to the policy's selection criteria.

Physician prescription and justification required for form‑fitting garments

When a form‑fitting conductive garment is used, include a physician prescription and justification describing why conventional electrodes are impractical and documentation that the garment is FDA‑marketed (HCPCS E0731).

• Prescriber statement explaining large stimulation area, skin issues, or cast application that preclude conventional electrodes.
• Evidence of FDA marketing/clearance for the specific garment model.

Support all stimulator/lead/implant claims with medical necessity documentation

When billing covered HCPCS/CPT for stimulators, electrodes, leads, or implantable components, include medical necessity documentation that demonstrates the patient meets the policy's selection criteria for the specific code/device billed.

• Tie each billed code to the policy's listed covered codes and include clinical evidence that selection criteria are satisfied.
• Exclude billing codes that the policy lists as not covered for the indication.

Include laparoscopic motor point mapping and stimulation testing records for DPS

DPS implantation series referenced laparoscopic motor point mapping and intra‑muscular electrode implantation with perioperative assessments; include operative notes and stimulation testing records as applicable when seeking authorization.

• Attach laparoscopic motor point mapping reports, intra‑operative stimulation findings, and perioperative respiratory assessments.
• Include post‑operative conditioning/stimulation plans when available.

Document reflexes and cystometry thresholds for implant selection

For implanted sacral anterior root stimulation, document the presence of 3 of 4 non‑vesical sacral segment reflexes and cystometry showing phasic detrusor pressure thresholds (≥35 mm H2O female; ≥50 cm H2O male) to support implant candidacy.

• Provide cystometry reports and reflex testing documentation used to determine intact efferent supply to the bladder.
• Include trial stimulation/voiding trial results if performed.

Submit trial‑used objective outcome measures to support device benefit

Include objective functional outcome measures used in trials (e.g., 10‑m walk, 6‑minute walk, GaitRite FAP, mEFAP, Berg Balance Scale, TUG) when submitting medical necessity evidence for FES or wearable gait devices.

• Provide baseline and follow‑up scores for relevant functional tests to demonstrate treatment effect.
• If device is for balance/gait, include validated scales such as FGA or TUG as applicable.

Provide device history and battery depletion evidence for replacements

Provide operative/device history and justification for replacement claims (for example, evidence of battery depletion or device end‑of‑life such as mean Remede battery life ~4.2 years) to support implantable device replacement coverage.

• Attach prior implant operative reports, device interrogation showing battery status, and clinical rationale for replacement.
• Cite documented mean battery life where relevant (Remede ~4.2 years) to justify timing of replacement.

Provide test‑stimulation response and prior conservative management records for implants

When requesting coverage for permanent implantable neuromodulation, include documentation of test stimulation response and evidence of prior conservative management per trial designs and device selection practices.

• Attach test stimulation logs, symptom diaries, validated symptom scores, and a record of prior therapies and outcomes.
• Document any complications or reasons for proceeding to permanent implantation.

Include device usage logs and objective tremor metrics to support ongoing home‑use coverage

For continued home‑use coverage of tremor‑targeting devices, include device usage logs and objective outcome measures (e.g., TETRAS, BF‑ADL, wrist accelerometer tremor power) to document benefit over time.

• Submit device‑recorded accelerometry pre/post session metrics, clinician TETRAS scores, and patient BF‑ADL reports.
• Provide periodic follow‑up data showing sustained functional improvement to justify ongoing coverage.

Provide pre/post accelerometry and ADL assessments when using device logs in coverage decisions

If device logs or objective tremor measurements are used for coverage decisions, include pre/post postural hold accelerometry and ADL assessments as done in trials and post‑market studies.

• Provide examples of pre/post session accelerometry snapshots and associated ADL score changes.
• Include adherence data (frequency/duration of sessions) from device logs.